Join to view full profile
520 Country Club PkwyEugene, OR 97401
Phone+1 541-683-5001
Fax+1 541-683-1422
Dr. Yasenchak is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a lymphoma specialist, clinical researcher, and immunotherapy leader committed to bridging academic research with real-world oncology care, particularly for elderly and infirm patients. As CAR-T/Bispecifics Medical Director at Willamette Valley Cancer Institute, I lead a multidisciplinary team managing complex lymphoma cases, ensuring the safe and effective integration of CAR-T and bispecific antibody therapies into community-based practice.
A major focus of my work is improving treatment options for elderly and frail patients, who often face unique challenges in lymphoma care, including limited tolerance for intensive therapies. As a Principal Investigator within the US Oncology Research network, I lead clinical trials focused on novel therapies for Classical Hodgkin Lymphoma (CHL) and other lymphomas, with a specific emphasis on tailoring treatments for elderly and high-risk populations.
Additionally, as a Lymphoma Executive Committee Member at the Sarah Cannon Research Institute, I collaborate with global experts to translate the latest research into practical, community-based applications—helping expand access to innovative treatments beyond major academic centers.
Key areas of focus:
• Leadership in CAR-T and bispecific antibody therapies in community settings
• Principal investigator in clinical trials for elderly and infirm patients with lymphoma
• Advancing novel therapies for Classical Hodgkin Lymphoma in high-risk populations
• Multidisciplinary care and real-world application of immunotherapies
• Bridging academic research with practical applications in community-based oncology
Over the past decade, my research efforts have resulted in numerous peer-reviewed publications, conference presentations, and collaborations with leading lymphoma experts. I am committed to expanding access to novel, less toxic therapies for elderly patients who might not tolerate traditional treatments, ensuring that innovative breakthroughs reach those who need them
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2003 - 2006
Johns Hopkins UniversityFellowship, Allergy and Immunology, 2002 - 2003- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1999 - 2002
Pennsylvania State University College of MedicineClass of 1999
Certifications & Licensure
OR State Medical License 2006 - 2027
WA State Medical License 2006 - 2015
MN State Medical License 2000 - 2010
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification iKnowMed Generation 2, McKesson, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification iKnowMed™ EHR, US Oncology, 2012, 2014-2017
Clinical Trials
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2012 Oct 31
- BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
- MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Publications & Presentations
PubMed
- Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.Jeremy S Abramson, David J Straus, Nancy L Bartlett, John M Burke, Ryan C Lynch
Advances in Therapy. 2026-08-29 - Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.Jeremy S Abramson, David J Straus, Nancy L Bartlett, John M Burke, Ryan C Lynch
Future Oncology. 2026-07-01 - 6 citationsBrentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.Jeremy S Abramson, David J Straus, Nancy L Bartlett, John M Burke, Ryan C Lynch
Blood. 2026-04-09
Journal Articles
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaBeth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer
- An Open‐Label Phase 2 Trial of Entospletinib in Indolent Non‐Hodgkin Lymphoma and Mantle Cell LymphomaJeff P Sharman, David J Andorsky, Christopher A Yasenchak, Kathryn S Kolibaba, British Journal of Haematology
Authored Content
- Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018
Press Mentions
US Oncology Research Announces Schedule of Presentations at the 2019 American Society of Hematology Annual Meeting and ExpositionDecember 5th, 2019
Frontline Brentuximab Vedotin Generates 76% Complete Remission Rate in DLBCLDecember 22nd, 2015
More Treatment-Guiding Interim PET-CT Scans Needed in Advanced Stage Hodgkin LymphomaDecember 4th, 2023
Committees
- PI/SubI, Phase I Research Program. US Oncology Research. 2013 - Present
- PI/SubI, Hematology Research Program. US Oncology Research. 2008 - Present
Research History
- Associate Chair, Hematology Research Program. US Oncology Research2013 - Present
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: